Statistics from Altmetric.com
Cytokines are critical in initiating and perpetuating the chronic inflammatory response in primary Sjögren's syndrome (pSS).1 Rituximab has beneficial effects on disease activity in pSS patients2 and results in a rise in B cell activating factor (BAFF) levels.3 Whether (elevated) levels of other (proinflammatory) cytokines are affected was addressed in this study. This information is important for understanding of the effect of rituximab in pSS.
Twenty-eight patients with early-onset pSS2 treated with rituximab (n=18) or placebo (n=10), and 10 age-matched and sex-matched healthy controls (HCs) were assessed for presence of cytokines/chemokines in serum, using a multiplex-25 bead array assay (Invitrogen, Breda, The Netherlands). The following cytokines and chemokines were analysed: GM-CSF, IL-1β, IL-1Ra, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40/p70, IL-13, IL-15, IL-17, IFN-α, IFN-γ, TNF-α, MCP-1/CCL2, MIP-1α/CCL3; MIP-1β/CCL4, RANTES/CCL5, Eotaxin/CCL11, MIG/CXCL9 and IP-10/CXCL10.
At baseline, levels for nearly all cytokines/chemokines were significantly higher in pSS patients than …
RPEP and WHA contributed equally to this work.
ClinicalTrials.gov identifier: NCT00363350
Contributors None of the authors have financial interests that could create a potential competing interest or the appearance of a conflict of interest with regard to the work.
Funding Supported by unconditional grants of Roche (Woerden, The Netherlands) and the Jan-Kornelis de Cock foundation (Groningen, The Netherlands).
Competing interests None.
Patient consent Obtained.
Ethics approval The ethics committee of the University Medical Center Groningen (METC approval: 05.229).
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.